Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

In this RCT, apatinib, a novel inhibitor of vascular endothelial growth factor receptor-2, significantly improved overall survival in Chinese patients with pre-treated hepatocellular carcinoma vs placebo (n=400; median 8.7 vs 6.8 months; HR 0;785; 95% CI 0.617‒0.998; p=0.048).

Lancet Gastroenterology and Hepatology